Green Cross and Nanolek announced that they have entered into a strategic partnership agreement for the commercialization of Green Cross' biologics in the Russian market. Under the terms of the agreement, Nanolek will obtain marketing authorizations and set up the production of a number of Green Cross' biologics. The production will be organized at Nanolek's facility, a biopharmaceutical complex built and equipped in compliance with EU GMP standards and launched in December 2014.